Celera Genomics Announces the Sale of Its Cathepsin S Inhibitor Program to Schering AG; Transaction Completes Celera's Planned Exit from Small Molecule Development.
Linked as:
Extract
Celera Genomics Announces the Sale of Its Cathepsin S Inhibitor Program to Schering AG; Transaction Completes Celera's Planned Exit from Small Molecule Development.
ROCKVILLE, Md. -- Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that Schering AG has acquired its cathepsin S inhibitor small molecule drug program for the treatment of autoimmune diseases. The financial terms of the transaction include an upfront cash payment of $5 million, half of which is payable to Cel...
See the full content of this document
Sponsored links
